Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout
Biogen has struck a $5.6 billion deal to acquire Apellis Pharmaceuticals, adding Syfovre and Empaveli while expanding its rare disease and immunology growth portfolio.
Biogen agreed to acquire Apellis for $5.6 billion, adding Syfovre and Empaveli and strengthening its rare disease and immunology pipeline.
Key facts
- Biogen will acquire Apellis Pharmaceuticals in a deal valued at $5.6 billion.
- Biogen will pay $41 per share in cash at closing, a near 140% premium to Apellis’ 30 March closing stock price.
- The acquisition adds Syfovre and the U.S. commercial rights to Empaveli to Biogen’s portfolio.
- Biogen expects the deal to close in Q2 2026.
Biogen has forged a $5.6bn deal to acquire immunology and rare disease specialist Apellis Pharmaceuticals, marking another M&A milestone in a flurry of pharma deal activity at the end of Q1. This acquisition will add Syfovre and Empaveli to Biogen’s portfolio of medicines. As per the agreement, Biogen will pay $41 per share in cash at closing, a near 140% premium on the company’s 30 March closing stock price, to absorb a vast proportion of Apellis’ employee base and its portfolio of medicines.
This includes geographic atrophy therapy Syfovre (pegcetacoplan) and the U.S. commercial rights to kidney disease therapy Empaveli (pegcetacoplan), which pulled in a combined revenue of $689m in 2025. Biogen expects the drugs to continue on a mid-to-high teens upward trajectory until at least 2028.
Analyst consensus forecasts from GlobalData, parent company of Pharmaceutical Technology, currently predict that Syfovre and Empaveli will pull in $1bn and $747m in 2031, respectively. Those projections underline why Apellis was viewed as a strategically attractive target for Biogen as it looks to reinforce its growth profile with commercial-stage assets in rare disease and immunology.
Biogen adds Syfovre and Empaveli to strengthen growth portfolio
According to Biogen’s CEO, Christopher Viehbacher, the Apellis buyout will also provide Biogen with the expertise and field capabilities to support commercialization efforts for its late-stage kidney disease candidate, felzartamab. The Massachusetts-based pharma is currently evaluating the anti-CD38 therapy in primary membranous nephropathy (PMN), late antibody-mediated rejection (AMR) and immunoglobulin A nephropathy (IgAN).
Biogen expects this acquisition deal to close in Q2 2026. In a 31 March statement, Viehbacher noted that the Apellis acquisition would “immediately advance Biogen’s ongoing transformation” by expanding its growth portfolio and boosting its near- and long-term prospects.
Biogen said the Apellis acquisition would immediately advance its ongoing transformation by broadening its growth portfolio and improving both near-term and long-term prospects.
Deal could support commercial execution beyond current Apellis assets
Beyond the direct addition of Syfovre and Empaveli, the deal could also strengthen Biogen’s operating capabilities in nephrology and rare disease commercialization. The company believes Apellis’ expertise and field infrastructure may help support the future launch potential of felzartamab, giving the acquisition significance beyond the revenue contribution of currently marketed assets.
That strategic rationale is especially important as Biogen continues reshaping its business mix. The company has been working to diversify away from historical dependence on older franchises and toward newer growth drivers in rare disease, immunology and specialty medicine. From that perspective, the Apellis transaction is both a portfolio expansion move and a commercial capability play.
Investors question price despite long-term sales upside
Despite Biogen’s enthusiasm toward the deal, investors did not appear to share the same sentiment immediately after the announcement. Biogen’s stock value dropped by more than 4%, falling from $187.57 at market close on 30 March to $179.46 at the opening on 31 March after the news emerged.
According to William Blair analysts, Wall Street will likely debate the price paid for Apellis, but the buyout has the potential to add $1.54bn in sales to Biogen’s top line by 2030. The analysts also said the Apellis acquisition could help offset the near-term decline of Biogen’s multiple sclerosis franchise while providing prospects for longer-term growth.
Taken together, the transaction reflects Biogen’s willingness to pay a substantial premium for assets that can contribute immediately to revenue while also supporting its future strategic direction. If the company can integrate Apellis successfully and sustain growth for Syfovre and Empaveli, the $5.6bn buyout could become one of Biogen’s more important rare disease and immunology deals in recent years.
